Long-term studies of treatments for type 2 diabetes

被引:8
作者
Caballero, A. Enrique [1 ]
机构
[1] Harvard Med Sch, Joslin Diabet Ctr, Boston, MA USA
关键词
alpha-Glucosidase inhibitors; glucose-lowering therapies; incretin-based therapies; insulin; type; 2; diabetes; BETA-CELL FUNCTION; OBSERVATIONAL FOLLOW-UP; PIOGLITAZONE CLINICAL-TRIAL; METFORMIN-TREATED PATIENTS; GLYCEMIC CONTROL; CARDIOVASCULAR OUTCOMES; INSULIN GLARGINE; OPEN-LABEL; MACROVASCULAR DISEASE; JAPANESE PATIENTS;
D O I
10.1080/00325481.2017.1265417
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
There is a relative lack of long-term data for individual glucose-lowering therapies for the treatment of type 2 diabetes mellitus. A systematic search of published literature reporting data of approximately 3years of follow-up from randomized controlled trials and their extensions was conducted. Trials to evaluate the efficacy and/or safety of glucose-lowering drugs currently approved for the treatment of adults with type 2 diabetes were included. Search results included long-term published data for traditional oral glucose-lowering drugs, insulin, -glucosidase inhibitors, and incretin-based therapies. In general, results indicated that the short-term risk/benefit profile of these therapies is in line with longer-term evaluations. Individual results from these trials are reviewed in this report. These findings support the use of approved drug classes for longer-term treatment of type 2 diabetes.
引用
收藏
页码:352 / 365
页数:14
相关论文
共 69 条
  • [11] Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial
    de Jager, J.
    Kooy, A.
    Schalkwijk, C.
    van der Kolk, J.
    Lehert, P.
    Bets, D.
    Wulffele, M. G.
    Donker, A. J.
    Stehouwer, C. D. A.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2014, 275 (01) : 59 - 70
  • [12] From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
    DeFronzo, Ralph A.
    [J]. DIABETES, 2009, 58 (04) : 773 - 795
  • [13] Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
    Diamant, Michaela
    Van Gaal, Luc
    Guerci, Bruno
    Stranks, Stephen
    Han, Jenny
    Malloy, Jaret
    Boardman, Marilyn K.
    Trautmann, Michael E.
    [J]. LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (06) : 464 - 473
  • [14] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
    Dormandy, JA
    Charbonnel, B
    Eckland, DJA
    Erdmann, E
    Massi-Benedetti, M
    Kmoules, IK
    Skene, AM
    Tan, MH
    Lefébvre, PJ
    Murray, GD
    Standl, E
    Wilcox, RG
    Wlhelmsen, L
    Betteridge, J
    Birkeland, K
    Golay, A
    Heine, RJ
    Korányi, L
    Laakso, M
    Mokán, M
    Norkus, A
    Pirags, V
    Podar, T
    Scheen, A
    Scherbaum, W
    Schernthaner, G
    Schmitz, O
    Skrha, J
    Smith, U
    Taton, J
    [J]. LANCET, 2005, 366 (9493) : 1279 - 1289
  • [15] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study
    Drucker, Daniel J.
    Buse, John B.
    Taylor, Kristin
    Kendall, David M.
    Trautmann, Michael
    Zhuang, Dangliang
    Porter, Lisa
    [J]. LANCET, 2008, 372 (9645) : 1240 - 1250
  • [16] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
    Drucker, Daniel J.
    Nauck, Michael A.
    [J]. LANCET, 2006, 368 (9548) : 1696 - 1705
  • [17] Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes
    Erdmann, E.
    Harding, S.
    Lam, H.
    Perez, A.
    [J]. DIABETES OBESITY & METABOLISM, 2016, 18 (03) : 266 - 273
  • [18] Observational follow-up of the PROactive study: a 6-year update
    Erdmann, E.
    Song, E.
    Spanheimer, R.
    de Bruyn, A. -R. van Troostenburg
    Perez, A.
    [J]. DIABETES OBESITY & METABOLISM, 2014, 16 (01) : 63 - 74
  • [19] Frye RL., 2009, NEW ENGL J MED, V360, P2503, DOI [DOI 10.1056/NEJMOA0805796, 10.1056/NEJMoa0805796]
  • [20] Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial
    Gallwitz, Baptist
    Guzman, Juan
    Dotta, Francesco
    Guerci, Bruno
    Simo, Rafael
    Basson, Bruce R.
    Festa, Andreas
    Kiljanski, Jacek
    Sapin, Helene
    Trautmann, Michael
    Schernthaner, Guntram
    [J]. LANCET, 2012, 379 (9833) : 2270 - 2278